Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

177
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
177
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

166
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
166
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

206
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
206
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

143
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
143
  1. Home
  3. Impact Of Glucagon-like Peptide-1 Receptor Agonists On The Dementia Incidence In Patients With Type 2 Diabetes Mellitus: A Population-based Longitudinal Cohort Study.
  1. Home
  3. Impact Of Glucagon-like Peptide-1 Receptor Agonists On The Dementia Incidence In Patients With Type 2 Diabetes Mellitus: A Population-based Longitudinal Cohort Study.

Related Experiment Video

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.4K

Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes

Hung-Wen Cheng1,2, Shun-Fa Yang1,3, Pei-Lun Liao3

  • 1Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Diabetes/Metabolism Research and Reviews
|June 7, 2025

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
dementiaglucagon‐like peptide‐1 receptor agonists (GLP‐1RAs)type 2 diabetes mellitus (T2DM)

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

4.8K

Related Experiment Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.4K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

4.8K

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a reduced risk of dementia in type 2 diabetes patients. This finding suggests a potential neuroprotective effect of GLP-1RAs in managing diabetes-related cognitive decline.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Gerontology

Background:

  • Type 2 diabetes mellitus (T2DM) is a known risk factor for dementia.
  • Evidence for interventions to mitigate T2DM-related dementia risk is limited.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for T2DM management.

Purpose of the Study:

  • To investigate the association between GLP-1RAs use and the incidence of all-cause dementia in individuals with T2DM.
  • To determine if GLP-1RAs offer a protective effect against dementia development in this population.

Main Methods:

  • A retrospective cohort study of 109,778 individuals initiating GLP-1RAs or non-GLP-1RAs medications (2013-2021).
  • Propensity score matching and Cox proportional hazard models were used.
  • Adjusted hazard ratios (aHR) and confidence intervals (CI) were calculated to assess dementia risk.

    • Main Results:

    • GLP-1RAs use was associated with a significantly reduced risk of dementia (aHR, 0.90; 95% CI, 0.83-0.97).
    • Subgroup analyses confirmed lower dementia incidence in GLP-1RAs users across various diabetic complications.
    • A significant protective effect was observed in GLP-1RAs users aged 75 years or younger.

    Conclusions:

    • GLP-1RAs utilization is associated with a decreased incidence of dementia compared to non-GLP-1RAs medications.
    • These findings suggest GLP-1RAs may play a role in reducing dementia risk in T2DM patients.
    • Further research is warranted to explore the neuroprotective mechanisms of GLP-1RAs.